Results 81 to 90 of about 87,925 (315)
Journal of Analytical Methods in Chemistry, 2021 In this study, The metabolites, metabolic pathways, and metabolic fragmentation mode of a tyrosine kinase inhibitor- (TKI-) imatinib in rats were investigated.
Sijiang Liu, Zhaojin Yu
doaj +1 more source
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
New England Journal of Medicine, 2017 BACKGROUND Mast cells are present in the airways of patients who have severe asthma despite glucocorticoid treatment; these cells are associated with disease characteristics including poor quality of life and inadequate asthma control.
K. Cahill +17 more
semanticscholar +1 more source
Imatinibe mesilato no Brasil [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2005 Marcos LimaIt was the best of times, it was the worst of times,it was the age of wisdom, it was the age of foolishness,it was the epoch of belief, it was the epoch of incredulity,it was the season of Light, it was the season of Darkness,it was the spring of hope, it was the winter of despair,we had everything before us, we had nothing before us,we were
openaire +3 more sources
MiR‐221‐3p Attenuates IL‐33‐Induced Mast Cell Cytokine Expression by Targeting KIT
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Mast cells (MCs) are involved in type 2 inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP), which depends on interleukin (IL)‐33 stimulation. MiR‐221 is reported to be an important regulator of MCs, and miR‐221‐3p can be expressed in CRSwNP. However, the role of miR‐221‐3p in CRSwNP is unclear. Methods Ethmoid tissues
Ruowu Liu +11 more
wiley +1 more source
Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib
Turkish Journal of Hematology, 2011 Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity.
Semra Paydaş +2 more
doaj +3 more sources
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
New England Journal of Medicine, 2006 BACKGROUND Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a ...
H. Kantarjian +18 more
semanticscholar +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim This study builds on the environmental risk analysis presented in the 2022 National Report on Medicines Use in Italy by the Italian Medicines Agency and aims to assess the environmental risk posed by medicines in Italy and its regions. Methods The analysis selected 90 medicines based on three criteria: high utilization, low predicted no effect ...
Valentina Giunchi +8 more
wiley +1 more source
Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
Acta Medica Alanya, 2020 Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. [PDF]
PLoS ONE, 2010 The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure.
Jiye A +15 more
doaj +1 more source
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Journal of Community Hospital Internal Medicine Perspectives, 2018 Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias +3 more
doaj +1 more source